Medicus Pharma Ltd.
MDCXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for MDCX. That does not mean none is planned.
Get an email about MDCX's next catalysts
Track Medicus Pharma (MDCX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
2 upcoming events in our data (conference, earnings).See the timeline
2 upcoming, 0 past
Conference Presentation - CD228V
Medicus Pharma will host a Q3 2026 financial and business update call on November 9, 2026, to discuss its CD228V co-development and licensing agreement with Pfizer and a proposed SkinJect business combination with an undisclosed SPAC and concurrent financing (non-binding LOI).
SourceMDCX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-8.50 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
No drugs found in this phase.
Frequently asked questions
When is Medicus Pharma Ltd.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Medicus Pharma Ltd. (MDCX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MDCX biotech catalysts?→
Add MDCX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Medicus Pharma Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.